Intellia Therapeutics, which is developing gene editing therapies using CRISPR/Cas9 technology, filed on Monday with the SEC to raise up to $120 million in an initial public offering.
Fellow CRISPR gene editing biotech Editas Medicine (EDIT) went public in February with significant insider buying, and currently trades 137% above its offer price.
The Cambridge , MA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol NTLA. Intellia Therapeutics filed confidentially on September 4, 2015. Credit Suisse, Jefferies and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
